Why take this course?
Sponsor oversight under ICH-GCP E6(R3) places strengthened expectations on how sponsors direct, document, and demonstrate oversight of clinical trials, including activities performed by external suppliers. Inspection readiness therefore depends on more than having oversight responsibilities assigned. Sponsors need a clear strategy, supporting documentation, and contractual arrangements that show how oversight is planned and maintained in line with GCP expectations.
This webinar examines sponsor oversight requirements alongside common FDA and EMA inspection findings, connecting regulatory expectations with practical inspection preparation. Participants will consider what sponsor oversight means under E6(R3), what inspection readiness requires, and how oversight plans and records should support the sponsor’s approach. Particular attention is given to external suppliers, where responsibilities, contractual requirements, and the oversight strategy need to provide inspectors with clear evidence of how sponsor responsibilities are being addressed. The focus remains on translating strengthened oversight expectations into practical inspection preparation.
Key Areas Covered
Nelle Stocquart
Nelle Stocquart has worked in clinical research since 2003, with experience as a CRA and project manager across CROs and pharmaceutical companies. She has managed local and international Phase I through Phase IV studies and now works with Belgian government-funded academic studies. This background directly supports sponsor oversight, supplier management, clinical operations, and inspection-readiness considerations.
Commonly Asked Questions About This Subject
What evidence shows that a sponsor is actually exercising oversight rather than simply receiving reports from a CRO or other service provider?
Inspectors can distinguish routine information flow from active sponsor oversight. ICH E6(R3) uses a proportionate, risk-based framework, but transferring trial-related activities to service providers does not eliminate the sponsor's responsibility for appropriate oversight. U.S. Food and Drug Administration
Meeting minutes, dashboards, monitoring reports, and vendor scorecards provide useful records, but their presence alone says little about what the sponsor did with the information. Stronger evidence shows that emerging problems were recognized, challenged, escalated, followed through, and resolved.
This becomes particularly visible when a vendor misses milestones, produces recurring quality issues, or fails to meet an agreed requirement. An inspector may follow that issue through several months of records and ask when the sponsor became aware of it, who evaluated its significance, what action followed, and how effectiveness was confirmed.
Oversight is easier to defend when the documentation preserves that decision trail. A large volume of CRO reports carries limited weight if sponsor action cannot be reconstructed from them.
How should sponsor oversight change when a CRO consistently meets contractual KPIs but quality signals suggest deeper problems?
Contractual performance should not prevent escalation when evidence affecting participant protection or data reliability points in another direction. Under ICH E6(R3), quality management and oversight are intended to be proportionate to risks that matter to trial quality, rather than driven solely by operational performance measures. U.S. Food and Drug Administration
A CRO can meet timelines for monitoring visits, query resolution, enrollment, or report delivery while recurring deviations, protocol compliance problems, inconsistent monitoring conclusions, or data-quality concerns develop underneath those metrics.
The sponsor should examine whether its oversight measures are capable of detecting the problems that matter. If quality issues repeatedly appear outside the existing KPI framework, continuing to cite satisfactory vendor performance becomes difficult to defend.
The important evidence is how the sponsor responded once the discrepancy became visible. That may include deeper review, targeted oversight, revised indicators, escalation, corrective action, or reassessment of the service provider. A green dashboard should never prevent investigation of credible contradictory evidence.
When can risk-based sponsor oversight become too light to defend during an inspection?
Risk-based oversight becomes vulnerable when reduced activity is supported mainly by a low-risk classification rather than evidence showing why the chosen level of oversight remains sufficient. ICH E6(R3) supports proportionate approaches, with attention to factors critical to trial quality and risks to participant protection and data reliability. European Medicines Agency (EMA)
The difficult cases arise after the trial changes. A vendor initially assessed as low risk may take on additional responsibilities, performance may deteriorate, protocol complexity may increase, or recurring issues may emerge. If oversight intensity remains unchanged, the original rationale can become stale.
Inspectors are likely to be interested in the reasoning behind reduced oversight and whether that reasoning was revisited when new information appeared. "Risk based" by itself explains very little.
A defensible approach connects oversight frequency and depth to identifiable risks and current performance. It also establishes conditions that trigger increased scrutiny. Proportionality works only when the oversight model can respond when the risk picture changes.
What should a sponsor do when several service providers are involved in the same trial problem and each claims the failure occurred outside its responsibility?
The sponsor needs to reconstruct the activity across organizational boundaries and determine where control actually failed. Complex outsourcing arrangements can divide responsibilities among CROs, laboratories, technology providers, specialty vendors, and other parties, but fragmented contracts do not resolve gaps in trial execution.
This is where responsibility matrices and agreements are tested rather than merely reviewed. ICH E6(R3) emphasizes clear documentation of roles and responsibilities and appropriate oversight of delegated or transferred activities. European Medicines Agency (EMA)
A recurring inspection weakness is the gap between two apparently well-defined responsibilities. One provider believes another party verifies the data, manages an escalation, follows a safety issue, or controls a handoff. Each contract can look reasonable when examined separately.
The investigation should trace the failed activity end to end and identify ownership at every transition. If responsibility was genuinely ambiguous, correcting the immediate event is insufficient. The sponsor should address the governance gap that allowed an important trial activity to sit between contractual boundaries.
Your TalkFDA Webinar Experience
1. Confirmation
3. Join the Live Training
4. Watch Again Anytime
Testimonials
Ready to Strengthen Your Team? Let’s Build Your Training Plan.
Your team deserves the clarity.
Your organization deserves the confidence.
Upcoming Courses
Featured Courses
